U.S. Markets open in 3 hrs 11 mins

Gilead Sciences, Inc. (GILD)


NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
64.36+0.13 (+0.20%)
At close: 4:00PM EDT
People also watch
CELGBIIBAMGNBMYREGN
Interactive chart
Previous Close64.23
Open64.23
Bid64.07 x 200
Ask64.63 x 100
Day's Range64.12 - 64.64
52 Week Range63.88 - 88.85
Volume7,162,965
Avg. Volume7,962,959
Market Cap84.1B
Beta0.99
PE Ratio (TTM)6.80
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield2.08 (3.24%)
Ex-Dividend Date2017-03-14
1y Target EstN/A
Trade prices are not sourced from all markets
  • Investopedia16 hours ago

    Amgen's Woes: It Could Always Be Worse!

    Amgen may need to do a major acquisition to revive is stock price longterm

  • Cramer's lightning round: I've got a message for the struggling Gilead Sciences
    CNBC3 days ago

    Cramer's lightning round: I've got a message for the struggling Gilead Sciences

    Jim Cramer shares his take on caller favorite stocks, including this drugmaker.

  • Barrons.com4 days ago

    5 Reasons Big Biotech Could Gain 25%-30%

    Leerink analyst Geoffrey Porges sees a light at the end of the tunnel for Big Biotech. In a note published today, he predicted that the stocks in his coverage area could shake off the doldrums, and climb 25% to 30% in the next year, if “the group captures a re-rating back to the long term average relative multiple, and our generally positive view of the near and long term revenue and earnings outlook materializes.” That coverage universe includes AbbVie (ABBV), Alexion Pharmaceuticals (ALXN), Amgen (AMGN), Biogen (BIIB), Celgene (CELG), Gilead Sciences (GILD), Regeneron (REGN) and Vertex (VRTX). The smaller companies in the group offer the profile of earlier legions of biotech companies, whereas the mature companies in the group (GILD [MP], AMGN [MP], BIIB[MP]) face more near term downside than upside.